title: Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele.
authors.forename: Mona
authors.initials: M
authors.lastname: Anand
authors.forename: Jamshid
authors.initials: J
authors.lastname: Khorashad
authors.forename: David
authors.initials: D
authors.lastname: Marin
authors.forename: Jane F
authors.initials: JF
authors.lastname: Apperley
authors.forename: John M
authors.initials: JM
authors.lastname: Goldman
authors.forename: Jaspal Singh
authors.initials: JS
authors.lastname: Kaeda
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D016313:Genes, abl; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D010879:Piperazines / Q000008:administration & dosage*; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D011743:Pyrimidines / Q000008:administration & dosage*; D013997:Time Factors; D014158:Transcription, Genetic
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate